In laryngeal cancer, miR-217 exerts an anti-metastatic and antiproliferative effect via repression of its downstream target genes MTDH and the programmed cell death protein 1-ligand 1 (PD1-L1) (148) at the translational level. This evidence concerns the gene MTDH and laryngeal carcinoma.